Confidential  Page 1  
CLINICAL STUDY PROTOCOL 
 
A PHASE 1, DOUBLE-BLIND, 
PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE 
STUDY OF THE SAFETY, TOLERABILITY, AND 
PHARMACOKINETICS OF PMN310 INFUSIONS IN 
HEALTHY VOLUNTEERS 
 
 
 
 
Protocol Number: PMN310-101 
Protocol Date: 22 September 2023 
Protocol Version: 2.0, Amendment 1 
IND Number: 161194 
Sponsor: ProMIS Neurosciences, Inc. 
[ADDRESS_663603]  
Cambridge, MA [ZIP_CODE] 
 
 
Confidentiality Statement 
This study will be performed in compliance with Good Clinical Practices (GCP) and applicable regulatory 
requirements, including the archiving of essential documents.  Information contained in this protocol is 
confidential in nature, and may not be used, divulged, published or otherwise disclosed to others except to the 
extent necessary to obtain approval of the Institutional Review Board or Independent Ethics Committee, or as 
required by [CONTACT_2371].  Persons to whom this information is disclosed should be informed that this information is 
confidential and may not be further disclosed without the express permission of ProMIS Neurosciences.  
PMN310-101 Version 2.0; 22 September 2023
PMN310 ProMIS Neurosciences
Confidential Page 2PROTOCOL SIGNATURE [CONTACT_99445]: A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending 
Dose Study of the Safety, Tolerability, and Pharmacokinetics of 
PMN310 Infusions in Healthy Volunteers
Protocol Number: PMN310-101
Protocol Version: 2.0, Amendment 1
Study Phase: 1
Sponsor: ProMIS Neurosciences, Inc.
Sponsor Representatives
I, the undersigned, have read this protocol and confirm that to the best of my knowledge it 
accurately describes the planned conduct of the study.
Date 

PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 4 with standardized meals provided during inpatient stay.  On Day 1, subjects 
will be randomly assigned to receive either a single infusion of PMN310 or 
placebo (6:2 ratio).  After randomization on Day 1, study drug will be 
administered followed by [CONTACT_512819], tolerability, and PK data 
for 12 weeks postdose (outpatient follow-up period).  Following completion 
of the postdose outpatient follow-up period, subjects may return for an 
optional follow-up visit to evaluate PK, ADA, and exploratory biomarkers, 
if warranted by [CONTACT_512820].  The decision to recommend the optional 
follow-up visit will be made by [CONTACT_512821]. 
All dose cohorts will have lumbar punctures (LPs) performed on Day [ADDRESS_663604] of 8 subjects (6:2; PMN310:placebo).  To 
evaluate the short term safety and tolerability of PMN310, each cohort will 
enroll a sentinel group of 2 subjects (1:1, PMN310:placebo) who will be 
dosed prior to dosing the remaining 6 subjects in the cohort (5:1, 
PMN310:placebo).  The Safety Review Committee (SRC) will review all 
safety data collected through 48 hours postdose from the 2 sentinel subjects 
to determine the acceptability of proceeding with dosing of the remaining 
6 subjects in the cohort. 
Dose escalation to the next cohort will only occur after approval by [CONTACT_203851].  The SRC will determine the acceptability of proceeding with 
enrollment of the next cohort based on review of safety and any available 
PK data at the time of review through 7 days postdose for a minimum of 
6 of 8 subjects per cohort. 
In the event that important safety concerns are observed at any time during 
the study, administration of study drug will be paused, subjects in the 
subsequent cohort(s) will not receive further study drug until further review 
of the safety data has occurred, and subsequent recommendations and 
approval have been provided by [CONTACT_12217].  
Study Population: Inclusion Criteria: 
Subjects must meet all of the following inclusion criteria to be eligible for 
this study: 
1. Male and females, [ADDRESS_663605] agree 
to use 1 of the following methods of contraception considered to be 
highly effective (i.e., results in < 1% failure rate when used 
consistently and correctly) from Screening through [ADDRESS_663606] dose of study drug: 
PMN310-101 Version 2.0; [ADDRESS_663607] of child-bearing potential and the vasectomy (as 
communicated to the subject by [CONTACT_512822]) was 
medically assessed as surgically successful. 
 Stable hormonal contraception associated with inhibition of 
ovulation (including by [CONTACT_512823], 
transdermal, or depot regimen) for at least [ADDRESS_663608] not currently be breastfeeding.  
Accepted evidence (self-reported medical history is acceptable) 
includes:  History of sterilization surgery, including tubal ligation, tubal 
occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral 
oophorectomy. 
 Postmenopausal status (12 months with no menses and no 
alternative cause).  Postmenopausal status will be confirmed 
with a follicle-stimulating hormone (FSH) test at Screening 
(FSH > 40 mIU/mL).  If there is any doubt about a female -menopausal status the subject must use a form of 
highly effective birth control as noted in Inclusion Criterion 1a. 
2. Any non-vasectomized male subjects must agree to use barrier 
contraceptives (male or female partner condom, diaphragm, cervical 
cap, sponges) plus spermicide for [ADDRESS_663609] agree not to donate or preserve eggs (ova) for 
120 days after dosing. 
5. Medically healthy with no clinically significant or relevant 
abnormalities in medical history, physical exam, vital signs, ECG, or 
laboratory evaluations (hematology, chemistry, and urinalysis) as 
assessed by [CONTACT_737].  At the Ievaluations may be repeated at Screening or Baseline (pre-dose) to 
assess clinical significance of abnormalities prior to dosing. 
6. Confirmed to have acceptable venous access for blood collections and 
IV dosing administration of study medication. 
7. Has provided written informed consent. 
8. Body mass index is between 18 and 32 kg/m2 (inclusive).  
       
 
 
 
  
   
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 6 9. Screening magnetic resonance imaging (MRI) reveals normal 
appearance of the brain parenchyma, normal spacing of ventricular 
system and cisternal spaces and is without any significant abnormality, 
including, but not limited to evidence of prior microhemorrhages, 
lacunar infarcts, hemorrhage, or infarct > 1cm3, cerebral contusion, 
encephalomalacia, aneurysm, vascular malformation, subdural 
hematoma, hydrocephalus, space occupying lesion (e.g., abscess or 
brain tumor such as meningioma). 
Exclusion Criteria: 
Subjects having any of the following exclusion criteria are not eligible for 
this study: 
1. Current or recurrent disease (e.g., cardiovascular, neurological, renal, 
liver, gastrointestinal, malignancy, autoimmune disease, or other 
condition) that could affect the action, absorption or disposition of the 
investigational product, or could affect clinical or laboratory 
assessments. 
2. Clinically significant 12-lead ECG abnormality at Screening.  QT 
interval corrected by [CONTACT_6550] (QTcF) > [ADDRESS_663610] 
eligibility.  However, if repeat ECG confirms QTcF > [ADDRESS_663611] is not eligible for this study. 
3. Systolic blood pressure > 150 bpm or diastolic blood pressure  
> 90 bpm (measured in supi[INVESTIGATOR_55848] [ADDRESS_663612]) at 
Screening.  Blood pressure may be repeated from the first assessment 
collected at Screening.  lood pressure may be 
used to determine subject eligibility. 
4. Experienced a significant systemic illness, as judged by [CONTACT_3786], within [ADDRESS_663613] or procedures. 
6. Currently using any medication (including over-the-counter or herbal, 
homeopathic preparations) except for acetaminophen as needed for 
miscellaneous aches and pains. 
7. History of alcohol abuse and/or illicit drug use within 12 months prior 
dosing or a smoking history (use of tobacco products). 
8. Unwilling to refrain from ingesting alcohol from Screening through 
Day 15 and unwilling to from 
Day 15 for the duration of the study; 1 drink is 5 ounces (150 mL) of 
wine, 12 ounces (360 mL) of beer, or 1.5 ounces (45 mL) of hard 
liquor. 
9. Positive urine drug screen for drugs of abuse or cotinine, or positive 
serum alcohol at Screening or Day -1.            
         
         
   
      
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 10 TABLE OF CONTENTS 
PROTOCOL SIGNATURE [CONTACT_1783] .................................................................................................2  
PROTOCOL SYNOPSIS ................................................................................................................3  
1. INTRODUCTION ......................................................................................................16  
1.1.  ...................................................................................................16  
1.1.1.  ............................................16  
1.2. PMN310 ......................................................................................................................17  
1.2.1. Nonclinical Studies .....................................................................................................17  
1.3. Study Rationale ...........................................................................................................19  
1.4. Rationale for Dose Selection ......................................................................................19  
1.5. Benefit-Risk Assessment ............................................................................................20  
2. STUDY OBJECTIVES AND ENDPOINTS ..............................................................21  
2.1. Study Objectives .........................................................................................................21  
2.1.1. Primary Objectives .....................................................................................................21  
2.1.2. Secondary Objectives .................................................................................................21  
2.1.3. Exploratory Objectives ...............................................................................................21  
2.2. Study Endpoints ..........................................................................................................21  
2.2.1. Primary Endpoints ......................................................................................................21  
2.2.2. Secondary Endpoints ..................................................................................................21  
2.2.3. Exploratory Endpoints ................................................................................................21  
3. STUDY DESIGN .......................................................................................................22  
3.1. Design Characteristics ................................................................................................22  
3.1.1. Dose Escalation Rules ................................................................................................22  
3.1.2. Safety Review Committee ..........................................................................................24  
4. STUDY POPULATION .............................................................................................25  
4.1. Inclusion Criteria ........................................................................................................25  
4.2. Exclusion Criteria .......................................................................................................26  
5. STUDY TREATMENTS............................................................................................28  
5.1. Identification and Description of Study Drug ............................................................28  
5.1.1. PMN310 ......................................................................................................................28  
5.1.2. Placebo ........................................................................................................................28  
5.2. Study Drug Preparation and Administration ..............................................................28    
      
PMN310-101 Version 2.0; [ADDRESS_663614] .........................................................................29  
5.5. Dose Escalation/Stoppi[INVESTIGATOR_1869] .................................................................................29  
5.6. Storage, Handling, and Accountability of Study Drug ...............................................29  
5.7. Prior and Concomitant Therapy ..................................................................................30  
5.7.1. Prohibited Medications ...............................................................................................30  
6. STUDY PROCEDURES BY [CONTACT_512824] ......................................................................31  
6.1. Screening Period (Day -28 to Day -1) ........................................................................31  
6.2. Inpatient Period (Days -1, 1, 2, 3, and 4) ....................................................................32  
[IP_ADDRESS]. Day -1 (Day of Admission to the Study Clinic) .........................................................32  
[IP_ADDRESS]. Day 1 (Day of Study Drug Administration) ...............................................................33  
[IP_ADDRESS]. Day 2 ...........................................................................................................................33  
[IP_ADDRESS]. Day 3 ...........................................................................................................................34  
[IP_ADDRESS]. Day 4 ...........................................................................................................................34  
6.2.2. Outpatient Period (Days 8, 15, 29, 43, 57, and 85) ....................................................35  
[IP_ADDRESS]. Day 8 ...........................................................................................................................35  
[IP_ADDRESS]. Day 15 .........................................................................................................................35  
[IP_ADDRESS]. Day 29 .........................................................................................................................36  
[IP_ADDRESS]. Day 43 .........................................................................................................................36  
[IP_ADDRESS]. Day 57 .........................................................................................................................37  
[IP_ADDRESS]. Day 85 .........................................................................................................................37  
6.2.3. Optional Follow-Up Visit  Day 120 .........................................................................38  
6.3. Early Termination .......................................................................................................38  
7. DESCRIPTION OF STUDY PROCEDURES ...........................................................39  
7.1.1. Demography and Medical History ..............................................................................39  
7.1.2. Columbia-Suicide Severity Rating Scale ....................................................................39  
7.1.3. Physical Examination .................................................................................................39  
7.1.4. Neurological Exam .....................................................................................................39  
7.1.5. Vital Signs ..................................................................................................................40  
7.1.6. Body Measurements ...................................................................................................40  
7.1.7. Magnetic Resonance Imaging .....................................................................................40  
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 12 7.1.8. Electrocardiogram .......................................................................................................40  
7.1.9. Laboratory Assessments .............................................................................................40  
7.1.10. Pharmacokinetic Sampling .........................................................................................41  
7.1.11. Antidrug Antibodies ...................................................................................................41  
7.1.12. Exploratory Biomarkers ..............................................................................................41  
7.1.13. Lumbar Puncture ........................................................................................................42  
7.1.14. Concomitant Medication Use .....................................................................................42  
7.1.15. Adverse Events ...........................................................................................................42  
[IP_ADDRESS].  Definition of a Serious Adverse Event .......................................................................43  
[IP_ADDRESS].  Assessment of Adverse Event Severity ......................................................................44  
[IP_ADDRESS].  Assessment of Causality .............................................................................................44  
[IP_ADDRESS].  Assessment of Expectedness ......................................................................................45  
[IP_ADDRESS].  Procedures for Eliciting and Recording Adverse Events ...........................................45  
[IP_ADDRESS].  Reporting Periods for Adverse Events and Serious Adverse Events .........................46  
[IP_ADDRESS].  Recording Serious Adverse Events ............................................................................46  
[IP_ADDRESS].  Reporting of Serious Adverse Events .........................................................................47  
[IP_ADDRESS].  Pregnancy ...................................................................................................................[ADDRESS_663615] DISCONTINUATION .........................49  
8.1. Study Termination ......................................................................................................49  
8.2. Removal or Early Withdrawal of Subjects from Therapy or Assessment ..................49  
8.2.1. Removal of Subjects from Therapy or Assessment ....................................................49  
[IP_ADDRESS]. Potential Criteria for Withdrawal from Study ............................................................49  
8.2.2. Definite Criteria for Withdrawal from Study .............................................................50  
8.3. Replacement of Study Subjects ..................................................................................50  
9. STATISTICAL ANALYSIS PLAN ...........................................................................51  
9.1. General Overview .......................................................................................................51  
9.2. Determination of Sample Size ....................................................................................51  
9.3. Analyzed Population Sets ...........................................................................................51  
9.4. Statistical Analyses .....................................................................................................51  
9.4.1. Safety Analysis ...........................................................................................................51  
9.4.2. Pharmacokinetic Analysis ..........................................................................................51  
10. QUALITY CONTROL AND QUALITY ASSURANCE .........................................53  
10.1. Study Monitoring and Site Audits ..............................................................................53  
PMN310-101 Version 2.0; [ADDRESS_663616] of the Study ......................................................................................55  
11.3. Protocol Revisions and/or Deviations ........................................................................[ADDRESS_663617] OF TABLES 
Table 1: Classification of Adverse Events by [CONTACT_141471] ............................................................44  
Table 2: Timeline for Reporting Serious Adverse Events ........................................................[ADDRESS_663618] OF FIGURES 
Figure 1:  PMN310-101 Study Schema Per Cohort ....................................................................23  
 
PMN310-101 Version 2.0; [ADDRESS_663619] deviation 
SPR surface plasma resonance 
SRC Safety Review Committee 
t1/2 terminal half-life 
T2/FLAIR T2-weighted fluid-attenuated inversion recovery 
Tmax time to C max 
Vd volume of distribution 
 
  
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 18  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 20  
 
 
  Planned doses include 
175 mg, 350 mg, 700 mg, 1400 mg and 2800 mg (optional).  Additional dose levels may be 
added to explore intermediate doses in lieu of the predefined doses.  Any intermediate doses will 
be selected in accordance with the safety and tolerability data reviewed by [CONTACT_7176] (SRC), and will not exceed a single dose of 2800 mg. 
1.5. Benefit-Risk Assessment 
PMN310 has not yet been evaluated in humans and the predicted safety and toxicology findings 
can only be garnered by [CONTACT_512825]-compliant toxicology studies in non-human 
primates.   
 
 
 
 
 
 
The safety of PMN310 will be assessed throughout the study by [CONTACT_42466], using criteria 
proposed by [CONTACT_512826]., 2010 , clinical laboratory assessments, vital sign measurements, 
physical and neurological examinations, 12-lead ECG measurements, and magnetic resonance 
imaging (MRI) evaluations. 
There are no expected direct health benefits to subjects in Study PMN310-101.  The safety, 
tolerability, and PK data collected in Study PMN310-101 will provide initial data supporting the 
evaluation of PMN310 in patients with AD. 

PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 21 2. STUDY OBJECTIVES AND ENDPOINTS 
2.1. Study Objectives 
2.1.1. Primary Objectives 
 To assess safety and tolerability of escalating doses of PMN310 when administered as 
a single IV infusion in healthy volunteers 
2.1.2. Secondary Objectives 
 To assess the single dose PK of PMN310 
2.1.3. Exploratory Objectives 
 To assess the immunogenicity of PMN310 following single dose administration 
 To assess biomarkers in healthy subjects 
2.2. Study Endpoints 
2.2.1. Primary Endpoints 
 Adverse events (AEs), clinical laboratory tests (clinical chemistry, hematology, 
urinalysis), physical and neurological examinations, vital signs, and 12-lead ECGs 
2.2.2. Secondary Endpoints 
 Serum PK: maximum observed concentration (C max), time to C max (Tmax), area under 
the curve from Time [ADDRESS_663620] sampling time (AUC 0-t), area under the curve from 
Time 0 to infinity (AUC 0-), terminal half-life (t 1/2), volume of distribution (Vd), 
clearance (CL) 
 Cerebrospi[INVESTIGATOR_872] (CSF) drug concentrations 
2.2.3. Exploratory Endpoints 
 Incidence and titers of ADAs 
 Residual and unused serum and CSF samples will be stored for future use for the 
measurement of biomarkers  
 
 
 
 
 
 
 
  
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 22 3. STUDY DESIGN 
3.1. Design Characteristics 
This is a randomized, placebo-controlled, single ascending dose clinical study of PMN310 in 
healthy adult volunteers.  The study aims to establish the safety, tolerability, and PK of a single 
IV infusion of PMN310.  
Subjects who provide written informed consent and meet all eligibility criteria will be admitted 
to the study clinic on Day -1 (i.e., the day prior to dosing with PMN310 or placebo).  Subjects 
will be domiciled for 4 nights with standardized meals provided during inpatient stay.  On Day 1, 
subjects will be randomly assigned to receive either a single infusion of PMN310 or placebo (6:2 
ratio).  After randomization on Day 1, study drug will be administered followed by [CONTACT_512827], tolerability, and PK data for 12 weeks postdose (outpatient follow-up period).  
Following completion of the postdose outpatient follow-up period, subjects may return for an 
optional follow-up visit to evaluate PK, ADA, and exploratory biomarkers, if warranted by 
[CONTACT_512820].  The decision to recommend the optional follow-up visit will be made by [CONTACT_512828]. 
All dose cohorts will have lumbar punctures (LPs) performed on Day [ADDRESS_663621] of 8 subjects (6:2; PMN310:placebo).  To evaluate the short term 
safety and tolerability of PMN310, each cohort will enroll a sentinel group of 2 subjects (1:1, 
PMN310:placebo) who will be dosed prior to dosing the remaining 6 subjects in the cohort (5:1, 
PMN310:placebo).  The first two sentinel subjects for Cohort 1 (age < 50) will have MRIs 
performed and read locally.  The SRC will review all safety data collected through 48 hours 
postdose from the 2 sentinel subjects to determine the acceptability of proceeding with dosing of 
the remaining 6 subjects in the cohort.  Additional details on the SRC are provided in 
Section 3.1.2 . 
Dose escalation to the next cohort will only occur after approval by [CONTACT_12217].  The SRC will 
determine the acceptability of proceeding with enrollment of the next cohort based on review of 
safety and any available PK data at the time of review through 7 days postdose for a minimum of 
6 of 8 subjects per cohort.  Doses to be evaluated are presented in Section 5.2.1 . 
In the event that important safety concerns are observed at any time during the study, 
administration of study drug will be paused, subjects in the subsequent cohort(s) will not receive 
further study drug until further review of the safety data has occurred, and subsequent 
recommendations and approval have been provided by [CONTACT_12217].  Dose escalation/stoppi[INVESTIGATOR_512806] 5.5 . 
A schematic illustrating the study design is provided in Figure 1. 
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 24 3.1.2. Safety Review Committee 
The SRC will be responsible for the review of safety and any available PK data at the time of 
review, and making determinations regarding the acceptability of proceeding with dosing of the 
remaining 6 subjects in a cohort (based on review of sentinel subjects) and dose escalation to the 
next cohort.  The SRC will be comprised of the Study Investigator, Medical Monitor, and 
Sponsor Medical Director.  At a minimum, the SRC will review safety data assessments 
post-dose for a minimum of 6 of 8 subjects per cohort prior to each dose escalation.  The SRC 
charter will specify operational details pertaining to roles and responsibilities, data to be 
reviewed, review frequency, and reporting.                 
PMN310-101 Version 2.0; [ADDRESS_663622] meet all of the following inclusion criteria to be eligible for this study: 
1. Male and females, [ADDRESS_663623] agree to use 1 of the following methods of contraception 
considered to be highly effective (i.e., results in < 1% failure rate when used 
consistently and correctly) from Screening through [ADDRESS_663624] dose of 
study drug:  Intrauterine device or intrauterine system in place for at least [ADDRESS_663625] of child-bearing potential and the vasectomy (as 
communicated to the subject by [CONTACT_512822]) was medically assessed 
as surgically successful.  Stable hormonal contraception associated with inhibition of ovulation (including 
by [CONTACT_512823], transdermal, or depot regimen) for at least 
[ADDRESS_663626] not currently be 
breastfeeding.  Accepted evidence (self-reported medical history is acceptable) 
includes:  History of sterilization surgery , including tubal ligation, tubal occlusion, 
hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy. 
 Postmenopausal status (12 months with no menses and no alternative cause).  
Postmenopausal status will be confirmed with a follicle-stimulating hormone 
(FSH) test at Screening (FSH > 40 mIU/mL).  If there is any doubt about a female 
-menopausal status the subject must use a form of highly effective 
birth control as noted in Inclusion Criterion 1a. 
2. Any non-vasectomized male subjects must agree to use barrier contraceptives (male or 
female partner condom, diaphragm, cervical cap, sponges) plus spermicide for [ADDRESS_663627] 200 days after dosing.  
  
PMN310-101 Version 2.0; [ADDRESS_663628] agree not to donate or preserve eggs (ova) for 120 days after dosing. 
5. Medically healthy with no clinically significant or relevant abnormalities in medical 
history, physical exam, vital signs, ECG, or laboratory evaluations (hematology, 
chemistry, and urinalysis) as assessed by [CONTACT_737].  At the Ilaboratory evaluations may be repeated at Screening or Baseline (pre-dose) to assess 
clinical significance of abnormalities prior to dosing. 
6. Confirmed to have acceptable venous access for blood collections and IV dosing 
administration of study medication. 
7. Has provided written informed consent. 
8. Body mass index is between 18 and 32 kg/m2 (inclusive). 
9. Screening MRI reveals normal appearance of the brain parenchyma, normal spacing of 
ventricular system and cisternal spaces and is without any significant abnormality, 
including, but not limited to evidence of prior microhemorrhages, lacunar infarcts, 
hemorrhage, or infarct > 1cm3, cerebral contusion, encephalomalacia, aneurysm, vascular 
malformation, subdural hematoma, hydrocephalus, space occupying lesion (e.g., abscess 
or brain tumor such as meningioma). 
4.2. Exclusion Criteria 
Subjects having any of the following exclusion criteria are not eligible for this study: 
1. Current or recurrent disease (e.g., cardiovascular, neurological, renal, liver, 
gastrointestinal, malignancy, autoimmune disease, or other condition) that could affect 
the action, absorption or disposition of the investigational product, or could affect clinical 
or laboratory assessments. 
2. Clinically significant 12-lead ECG abnormality at Screening.  QT interval corrected by 
[CONTACT_6550] (QTcF) > [ADDRESS_663629] eligibility.  However, if repeat ECG confirms QTcF > [ADDRESS_663630] is not 
eligible for this study. 
3. Systolic blood pressure > 150 bpm or diastolic blood pressure > 90 bpm (measured in 
supi[INVESTIGATOR_55848] [ADDRESS_663631]) at Screening.  Blood pressure may be repeated 
from the first assessment collected at Screening.  ure may be used to 
determine subject eligibility. 
4. Experienced a significant systemic illness, as judged by [CONTACT_737], within [ADDRESS_663632] or procedures. 
6. Currently using any medication (including over-the-counter, herbal or homeopathic 
preparations) except for acetaminophen as needed for miscellaneous aches and pains.    
           
       
            
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 27 7. History of alcohol abuse and/or illicit drug use within 12 months prior dosing or a 
smoking history (use of tobacco products). 
8. Unwilling to refrain from ingesting alcohol from Screening through Day 15 and 
unwilling to  from Day 15 for the duration of the 
study; 1 drink is 5 ounces (150 mL) of wine, 12 ounces (360 mL) of beer, or 1.5 ounces 
(45 mL) of hard liquor. 
9. Positive urine drug screen for drugs of abuse or cotinine, or positive serum alcohol at 
Screening or Day -1. 
10. Any significant concomitant disorder, including active bacterial, fungal, or viral 
infection, incompatible with participation in the study. 
11. History of prior malignancy (except adequately treated non melanoma skin cancer or 
carcinoma in-situ of the cervix). 
12. Documented history of human immunodeficiency virus (HIV) antibody, or tested positive 
for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody at 
Screening. 
13. Donated blood or blood products (e.g., plasma, platelets) within [ADDRESS_663633] 30 days or 5 half-lives (if known) prior 
to Screening, whichever is longer. 
15. Contraindication to brain MRI. 
16. Contraindication to undergoing LP including: sensitivity to local anesthetic, international 
normalized ratio (INR) > 1.4 or other coagulopathy, platelet cell count of < 120,000/µL, 
infection at the desired LP site, current use of anti-coagulant medication except for low 
dose aspi[INVESTIGATOR_248], degenerative arthritis, spi[INVESTIGATOR_407271], back surgery, suspected increased 
intracranial pressure on history or neurologic exam, non-communicating hydrocephalus 
or intracranial mass, or prior history of spi[INVESTIGATOR_512807]/or other known 
clinically significant spi[INVESTIGATOR_512808]. 
17. Inability to undergo venipuncture or tolerate venous access. 
18. Indication of potential suicidality risk as identified by [CONTACT_716]: 
a. Lifetime history of recurrent serious or recurrent suicide behavior. 
b. to any suicide behavior question on the Columbia-Suicide Severity Rating Scale 
(C-SSRS) Baseline  Screening version. 
c. Suicidal ideation with intent or plan wi
response to Item 4 or 5 on the C-SSRS Baseline  Screening version. 
19. Any of the following: clinically significant abnormalities on vital signs, physical exam, or 
laboratory testing at Screening and Baseline (pre-dose) per Investigator discretion.          
               
        
PMN310-101 Version 2.0; [ADDRESS_663634] of 100 mL 0.9% NaCl. 
5.2. Study Drug Preparation and Administration 
5.2.1. PMN310 
Study medication will be prepared at the study clinic by [CONTACT_21703] (or designee) 
IV drug for infusion will be dispensed to staff who will administer study drug.  Specific 
instructions for preparation and administration of study medication will be provided in the 
Pharmacy Manual. 
PMN310 will be administered as a single IV infusion over 60 minutes in 0.9% NaCl, adjusted to 
a total volume of 100 mL, followed by a 15 minute 0.9% NaCl flush.  The complete infusion will 
consist of the IV infusion and the flush following the IV infusion. 
The following dose level cohorts are planned to be evaluated: 175 mg (starting dose level), 
350 mg, 700 mg, 1400 mg, and 2800 mg (optional cohort).  The rationale for selecting these dose 
levels is provided in Section 1.4. 
5.2.2. Placebo 
Placebo will be administered as a matching single IV infusion over 60 minutes, followed by a 
15 minute 0.9% NaCl flush.  The complete infusion will consist of the IV infusion and the flush 
following the IV infusion. 
5.3. Randomization and Blinding 
Once an eligible subject is at the study site and prepared to receive the study drug, the subject 
will be assigned the treatment allocation according to the randomization sequence.  The 
randomization sequence will be obtained by [CONTACT_22123]-generated random numbers and provided 
to unblinded study site staff members who will have primary responsibility for drug dispensing.  
Within each cohort, eligible subjects will be randomized to receive PMN310 (N = 6) or placebo 
(N = 2).  Subjects and study personnel will be aware of the dosage level but will be blinded to  
            
            

PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 29 the study drug administered (PMN310 or placebo).  Only unblinded study site staff members 
assigned to prepare study drug will know whether a subject receives PMN310 or placebo.  To 
maintain appropriate blinding, the unblinded pharmacist will consult the randomization 
acy staff will then 
provide prepared study drug in a blinded fashion to the Investigator (or designee) for infusion. 
5.4. Unblinding for an Individual Subject 
In case of an emergency, the Investigator has the sole responsibility of determining if unblinding 
rranted.  Blinding should only be broken in emergency situations 
when knowledge of the treatment assignment is required for the assurance of the safety of the 
subject and the medical management of the subject.  The Sponsor or representative should be 
contact[INVESTIGATOR_530], when possible, before breaking the blind except in emergency circumstances when the 
Investigator has the sole responsibility for determining the need to unblind.  Upon breaking the 
blind, the reason must be documented, and the Sponsor should be immediately notified.  The 
applicable standard operating procedures (SOPs) will be followed for breaking the blind.  
5.5. Dose Escalation/Stoppi[INVESTIGATOR_512809], Two or more of the 
subjects in a cohort develop Grade 2 AEs in the same category.   
 One or more subjects in a cohort develop Grade  3 AEs. 
 It is determined that the limit of safety and/or tolerability has been reached as 
determined by [CONTACT_12217].  
The Sponsor or SRC may pause and then stop dosing within a cohort or decide to not dose 
escalate to a higher dose if it is determined that any AE is occurring that is intolerable or poses a 
medically unacceptable safety risk. 
5.6. Storage, Handling, and Accountability of Study Drug 
PMN310 will be supplied directly to the study site.  The study site will acknowledge receipt of 
the shipment and record inventory and usage of study drug on a drug disposition form.  Upon 
arrival at the study site, vials will be stored frozen at -25ºC to -15ºC (-13°F to 5°F) inside the 
cartons to minimize exposure to light, with the cartons oriented such that the enclosed vials are 
in the upright position.  An unblinded study monitor will perform reconciliation of the drug 
product. 
Used vi 
Unused vials will be either destroyed at the study site or returned to the Sponsor, as agreed 
between the site and Sponsor.  Before disposal/destruction of unused vials, final drug 
accountability and reconciliation must be performed by [CONTACT_115970].  
Documentation of destruction of vials of PMN310 must be available for review by [CONTACT_8760].                
           
      
 
  
 
             
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 30 5.7. Prior and Concomitant Therapy 
5.7.1. Prohibited Medications 
All medications, including over-the-counter, herbal, or homeopathic preparations (except for 
acetaminophen as needed for miscellaneous aches and pains), are prohibited during the study, 
unless required to be administered for the treatment of an AE.  Subjects receiving a stable dose 
of medications for high blood pressure or high cholesterol may be included with Sponsor 
approval. 
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 31 6. STUDY PROCEDURES BY [CONTACT_512829], Inpatient, and Outpatient periods are summarized in 
Appendix 1 . 
For each study day described below, when multiple procedures are scheduled at the same 
nominal time relative to dosing, the following chronology of events should be adhered to, where 
possible: 
 Vital signs and ECGs will be obtained as close as possible to the scheduled time (up 
to 45 minutes before PK sampling), but before blood specimen collection. 
 Serum PK samples will be obtained at the scheduled time. 
 After venipuncture, PK samples will be obtained first followed by [CONTACT_512830]. 
In the case of a clinical or laboratory abnormality, the Investigator may apply clinical judgement 
in repeating the measurement if the abnormality is believed likely to be an error. 
6.1. Screening Period (Day -28 to Day -1) 
Healthy volunteers will be recruited for this clinical study.  Before initiation of screening 
assessments, the subject must be given a complete explanation of the purpose and procedures 
occurring during the study.  Subsequently, the subject must sign and receive a copy of an 
Institutional Review Board (IRB)-approved informed consent form (ICF) ( Section 11.4 ).  Once 
informed consent has been obtained, screening assessments will be performed and eligibility of 
the subject will be determined based on the inclusion and exclusion criteria.  Subjects who fail 
screening may be rescreened following Sponsor approval. 
Study assessments are described in Section 7 . 
 
 Demography and medical history 
 Suicidality evaluation: C-SSRS (Baseline - Screening version) 
 Height 
 Complete physical examination 
 Neurologic examination 
 Vital signs 
 Weight 
 MRI 
 Lumbar x-rays 
puncture) 
 12-lead ECG 
 HBsAg and HCV tests  
 
 
              
  
 
   
 
  
 
 
          
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 32  FSH (post-menopausal women only) 
 Pregnancy test (non-post-menopausal women only) 
 Urine drug, urine cotinine, and serum alcohol screen 
 Clinical laboratory tests:  
 Blood chemistry and hematology 
 Urinalysis 
 Coagulation 
 Review of concomitant medications 
 AE assessment of protocol related procedures only, to be performed after informed 
consent is obtained 
The Investigator may use clinical judgment when determining the clinical significance of 
laboratory results throughout the study.  The Medical Monitor may, depending on study criteria, 
be consulted before enrollment of a candidate with abnormal laboratory values. 
6.2. Inpatient Period (Days -1, 1, 2, 3, and 4) 
During the inpatient period, standardized breakfast, lunch, and dinner will be provided at fixed 
times.  Meals are to be consumed within 45 minutes.  Evening snacks will be provided at a 
consistent time each day.  Fluids will be allowed liberally. 
[IP_ADDRESS]. Day -1 (Day of Admission to the Study Clinic) 
On Day 1 eligibility will be confirmed and eligible subjects will be admitted to the study clinic.  
Admission should occur before 6 PM.   
The following assessments will be performed: 
 Complete physical examination 
 Neurologic examination 
 Vital signs 
 Weight 
 12-lead ECG 
 Pregnancy test (non-post-menopausal women only) 
 Urine drug, urine cotinine, and serum alcohol screen 
 Clinical laboratory tests:  
 Blood chemistry and hematology 
 Urinalysis 
 Coagulation 
 ADA serum sampling  
   
 
 
 
 
 
  
 
 
 
 
PMN310-101 Version 2.0; [ADDRESS_663635] will remain in the study clinic overnight. 
[IP_ADDRESS]. Day 1 (Day of Study Drug Administration) 
Subjects will be randomly assigned to study drug (PMN310 or placebo).  After consumption of a 
standard breakfast, and pre-dosing assessments, study drug will be administered as an IV 
infusion as described in Section 5.2 .  After administration of study drug, inpatient follow-up data 
collection will include the following: 
 C-SSRS (Since Last Visit version) 
 Vital signs 
 12-lead ECG 
 PK serum sampling: before infusion, at the end of infusion (see Section 5.2.1  for a 
definition for complete infusion), and at 0.5, 1, 2, 4, 8, and 12 hours after the end of 
infusion. 
 Acceptable windows for PK sampling are as follows (exact time of PK collection 
is to be recorded):  
 Pre-dose sample to be collected within [ADDRESS_663636]-dose samples to be collected ± [ADDRESS_663637]-dose samples to be collected ± [ADDRESS_663638] will remain in the study clinic overnight. 
[IP_ADDRESS]. Day 2 
On Day 2, subjects will undergo the following assessments: 
 Vital signs  
 12-lead ECG 
 PK serum sampling at 24 and 36 hours from end of Day 1 infusion  
 Acceptable windows for PK sampling are ± 30 minutes (exact time of PK 
collection is to be recorded) 
 Review of concomitant medications 
 AE assessment 
The subject will remain in the study clinic overnight.  
 
 
 
 
  
 
 
 
 
 
 
  
 
 
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 34 [IP_ADDRESS]. Day 3 
On Day 3 subjects will undergo the following assessments: 
 Symptom directed physical examination 
 Neurologic examination 
 Vital signs 
 Weight 
 12-lead ECG 
 Clinical laboratory tests:  
 Blood chemistry and hematology 
 Urinalysis 
 Coagulation 
 PK serum sampling 72 hours from end of Day 1 infusion 
 Acceptable window for PK sampling is ± 60 minutes (exact time of PK collection 
is to be recorded) 
 LP. INR/PT/partial thromboplastin time (PTT) and platelet results within [ADDRESS_663639] will remain in the study clinic overnight. 
[IP_ADDRESS]. Day 4 
On Day 4, subjects will undergo the following assessments: 
 C-SSRS (Since Last Visit version) 
 Vital signs  
 PK serum sampling 96 hours from end of Day 1 infusion 
 Acceptable window for PK sampling is ± 60 minutes (exact time of PK collection 
is to be recorded) 
 Review of concomitant medications 
 AE assessment 
Following the completion of assessments, unless the Investigator feels that a longer period of 
observation is warranted (e.g., due to side effects of the study drug or any study procedure), 
subjects will be discharged from the study clinic.  
 
 
   
 
 
 
 
 
 
 
 
 
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 35 6.2.2. Outpatient Period (Days 8, 15, 29, 43, 57, and 85) 
Subjects will return to the study site for follow-up outpatient visits on Days 8, 15, 29, 43, 57, and 
85. 
[IP_ADDRESS]. Day 8 
On Day 8 (±1 day), subjects will undergo the following assessments: 
 Vital signs 
 12-lead ECG 
 Pregnancy test (non-post-menopausal women only) 
 Urine drug, urine cotinine, and serum alcohol screen 
 Clinical laboratory tests:  
 Blood chemistry and hematology 
 Urinalysis 
 Coagulation 
 PK serum sampling 
 Review of concomitant medications 
 AE assessment 
[IP_ADDRESS]. Day 15 
On Day 15 (±1 day), subjects will undergo the following assessments: 
 Vital signs 
 Clinical laboratory tests:  
 Blood chemistry and hematology 
 Urinalysis 
 Coagulation 
 PK serum sampling 
 Possible LP. INR/ PT/PTT and platelet results within [ADDRESS_663640] LP, subjects will remain supi[INVESTIGATOR_2525] a minimum of 4 hours, and may be kept 
longer for observation at the discretion of the Investigator.  After the 4-hour 
observation period, safety and tolerability will be assessed and subjects will be 
discharged home 
 Review of concomitant medications 
 AE assessment  
 
 
  
 
 
 
 
 
 
 
 
 
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 36 [IP_ADDRESS]. Day 29 
On Day 29 (±3 days), subjects will undergo the following assessments: 
C-SSRS (Since Last Visit version)
Symptom directed physical examination 
Neurologic examination 
Vital signs  
Weight 
12-lead ECG
Clinical laboratory tests:  
Blood chemistry and hematology 
Urinalysis 
Coagulation 
PK serum sampling 
ADA serum sampling 
Note:  Residual and unused serum and CSF samples will be stored for future use for 
the measurement of biomarkers LP. INR/PT/PTT and platelet results within [ADDRESS_663641] LP, subjects will remain supi[INVESTIGATOR_2525] a minimum of 4 hours, and may be kept 
longe
r for observation at the discretion of the Investigator.  After the 4-hour 
observation period, safety and tolerability will be assessed and subjects will be 
discharged home 
Review of concomitant medications 
AE assessment 
[IP_ADDRESS]. Day 43 
On Day 43 (±
3 days), subjects will undergo the following assessments: 
Vital signs 
MRI (subjects > 50 years of age only).  If ARIA is detected, subjects will return for 
addit
ional MRI assessments every 3-4 weeks until the ARIA resolves. 
Clinical laboratory tests:  
Blood chemistry and hematology 
Urinalysis 
Coagulation  
 
  
 
 
 
 
 
 
 
 
 
 
 
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 37  PK serum sampling 
 Review of concomitant medications 
 AE assessment 
[IP_ADDRESS]. Day 57 
On Day 57 (±3 days), subjects will undergo the following assessments: 
 C-SSRS (Since Last Visit version) 
 Vital signs 
 Clinical laboratory tests:  
 Blood chemistry and hematology 
 Urinalysis 
 Coagulation 
 PK serum sampling 
 ADA serum sampling 
 Note:  Residual and unused serum and CSF (if applicable) samples will be stored for 
future use for the measurement of biomarkers Possible LP. INR/ PT/PTT and platelet 
results within [ADDRESS_663642] LP, subjects will remain supi[INVESTIGATOR_2525] a minimum of 4 hours, and may be kept 
longer for observation at the discretion of the Investigator.  After the 4-hour 
observation period, safety and tolerability will be assessed and subjects will be 
discharged home 
 Review of concomitant medications 
 AE assessment 
[IP_ADDRESS]. Day 85 
On Day 85 (±4 days), subjects will undergo the following assessments: 
 C-SSRS (Since Last Visit version) 
 Symptom directed physical examination 
 Neurologic examination 
 Vital signs 
 Weight 
 12-lead ECG 
 Pregnancy test (non-post-menopausal women only) 
 Urine drug, urine cotinine, and serum alcohol screen  
  
 
  
 
 
 
 
 
 
 
 
  
 
  
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 38  Clinical laboratory tests:  
 Blood chemistry and hematology 
 Urinalysis 
 Coagulation 
 PK serum sampling 
 ADA serum sampling 
 Note:  Residual and unused serum and CSF samples (if applicable) will be stored for 
future use for the measurement of biomarkers Possible LP. INR/ PT/PTT and platelet 
results within [ADDRESS_663643] LP, subjects will remain supi[INVESTIGATOR_2525] a minimum of 4 hours, and may be kept 
longer for observation at the discretion of the Investigator.  After the 4-hour 
observation period, safety and tolerability will be assessed and subjects will be 
discharged home  Review of concomitant medications 
 AE assessment 
6.2.3. Optional Follow-Up Visit  Day 120 
The Day 120 visit (± 7 days) is optional.  Subjects who elect to participate in the Day 120 visit 
will undergo the following assessments: 
 PK serum sampling 
 ADA serum sampling 
 Note:  Residual and unused serum samples will be stored for future use for the 
measurement of biomarkers 
6.3. Early Termination 
If a subject cannot complete the entire study, efforts will be made to collect all prespecified 
assessments for Day 85 ( Appendix 1 ), if possible.  If a subject withdraws consent before early 
termination no further procedures should be performed and no additional data should be 
collected.  The Sponsor may retain and continue to use any data collected before the withdrawal 
of consent.  
 
 
 
 
 
 
 
 
PMN310-101 Version 2.0; [ADDRESS_663644] that systematically evaluates suicidal ideation and 
behavior.  The C-SSRS (Baseline - Screening and Since Last Visit versions) will be performed 
by a qualified trained rater. 
At Screening, the C-SSRS will be used to exclude any candidate with a history of suicide 
have experienced suicidal ideation associated with actual intent or plan within [ADDRESS_663645] be performed as soon as possible by a qualified mental health practitioner 
(with expertise in evaluation of suicidality) to determine whether it is safe for the subject to 
continue participation in the study. 
7.1.3. Physical Examination 
A full physical examination in this study will include the following: skin, eyes, ears, nose, oral 
mucosa, and throat, cardiac, respi[INVESTIGATOR_696], abdomen, and extremities.  
A symptom-directed physical examination will include both a full physical examination and a 
directed examination of the affected system related to any reported AE.  
Clinically relevant findings on the physical examination performed at Screening will be recorded 
as medical history.  Any clinically relevant treatment emergent new finding on examination will 
be documented as an AE. 
7.1.4. Neurological Exam 
Neurological examinations will include the following: mental status, level of consciousness, 
cranial nerve function, sensory function, motor function, and reflexes. 
Clinically relevant findings from the neurological examination performed at Screening will be 
recorded as medical history.  Any clinically relevant treatment-emergent new finding on 
examination will be documented as an AE.                  
                
PMN310-101 Version 2.0; [ADDRESS_663646] morning void.  
Microscopic examination will be performed if urinalysis results are abnormal for 
bacteria, casts, epi[INVESTIGATOR_1663], erythrocytes or leukocytes.  Urine should be collected 
within 1 hour of blood draws for hematology and chemistry panels.  Trace protein 
will be considered positive. 
 Coagulation panel, including (INR, PT, PTT and platelets); results within [ADDRESS_663647] be confirmed and determined to be within normal range before LP. 
Other laboratory tests include the following: 
 Viral serology, HBsAg and HCV tests 
 FSH for post-menopausal women only.  Post-menopausal status will be confirmed 
 
 Pregnancy test for non-post-menopausal women only (serum human chorionic 
gonadotropin at Screening and urinary chorionic gonadotropin thereafter).  If a urine 
pregnancy test is positive, a serum pregnancy test must be obtained. 
 Urine drug (amphetamines, methamphetamines, methadone, barbiturates, 
benzodiazepi[INVESTIGATOR_1651], cocaine, opi[INVESTIGATOR_858], methylenedioxymethamphetamine, phencyclidine, 
tetrahydrocannabinol), urine cotinine, and serum alcohol screen 
7.1.10. Pharmacokinetic Sampling 
Serum samples (approximately 5 mL) will be collected at the timepoints indicated in Appendix 1  
to assess the serum PK profile of PMN310.  On days when a PK sample is to be drawn and vital 
signs and/or an ECG are to be recorded, the PK sampling should be done shortly after 
completion of the vital signs and ECG.  Details for collection, handling, and shipment of 
specimens are provided in the Laboratory Manual. 
7.1.11. Antidrug Antibodies 
Serum samples will be collected to evaluate the levels of ADAs to PMN310 per the schedule in 
Appendix 1.  Details for collection, handling, and shipment of specimens are provided in the 
Laboratory Manual. 
7.1.12. Exploratory Biomarkers 
Residual and unused serum and CSF samples will be stored for the measurement of biomarkers 
at the timepoints outlined in Appendix 1.  Retaining surplus samples from scheduled PMN310-
101 study draws and lumbar punctures will be done for all subjects consenting to the study to  
 
 
 
 
       
 
 
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 43  All AEs (regardless of relationship to study drug) should be recorded from the time of 
informed consent through the follow-up visit at Week 12 (see Section [IP_ADDRESS] ).  
Complications that occur in association with any procedure should be recorded as 
AEs with assessed severity whether or not the procedure was protocol mandated. 
 In general, an abnormal diagnostic or laboratory value should not be recorded as an 
AE unless it is associated with clinical signs or symptoms (i.e., assessed as clinically 
significant), requires an intervention, results in an SAE, or results in study 
termination or interruption/discontinuation of study treatment.  When recording an 
AE resulting from a diagnostic or laboratory abnormality, the medical condition or 
diagnosis rather than the abnormality itself should be recorded (e.g.,  
[IP_ADDRESS]. Definition of a Serious Adverse Event 
In this study, an SAE is defined as an AE that meets any of the following criteria: 
 Results in death 
 Is life-threatening:  The term life-threatening in the definition of an SAE refers to an 
event in which the subject was at risk of death at the time of the event.  The term life 
threatening does not refer to an event that, had it occurred in a more severe form, 
might have caused death.   Requires hospi[INVESTIGATOR_26109] a prolongation of an existing hospi[INVESTIGATOR_059]:  In general, 
hospi[INVESTIGATOR_512810].  Complications that occur during 
hospi[INVESTIGATOR_1084], but not necessarily SAEs.  A medical occurrence or 
complication that prolongs hospi[INVESTIGATOR_61375].  When there is doubt as to 
whether hospi[INVESTIGATOR_51956], the AE should be considered an 
SAE.  Hospi[INVESTIGATOR_120874] a preexisting condition that did not 
worsen from its original baseline level is not considered an SAE. 
 A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions:  This does not include AEs of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza 
and accidental trauma (e.g., sprained ankle) that may interfere or prevent everyday 
life functions but do not constitute a substantial disruption. 
 A congenital anomaly or birth defect 
 Other important medical event:  Medical or scientific judgment should be exercised 
when deciding whether reporting is appropriate for other important medical events 
that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_512811].  These events should also be considered serious.  
Examples of such events are intensive treatment in an emergency room or at home for 
allergic bronchospasm, blood dyscrasias, or convulsions that do not result in 
hospi[INVESTIGATOR_512812].   
 
  
     
 
 
 
      
 
 
 
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 44 An SAE requires additional detailed reports and follow-up (see Section [IP_ADDRESS] ).  The content of 
these detailed reports must address the I  The Medical Monitor 
will review the SAE to determine if it is an expected SAE (i.e., whether or not the SAE is 
identified in nature, severity, and frequency in the Investigator Brochure). 
[IP_ADDRESS]. Assessment of Adverse Event Severity 
The Investigator will assess the intensity of each AE and SAE reported during the study on the 
basis of his or her clinical judgement. 
The classifications in Table 1 should be used in assigning intensity of each AE recorded in the 
CRF. 
Table 1: Classification of Adverse Events by [CONTACT_512831] (Grade) Definition 
Mild AE (Grade 1) An event that is easily tolerated by [CONTACT_423], 
causing minimal  discomfort and not interfering 
with everyday activities. 
Moderate AE  (Grade 2) Some interference with activity not requiring 
medical intervention 
Severe AE  (Grade 3)  Prevents daily activity and requires 
medical intervention 
 An event that, at the time of occurrence, 
put the subject at risk of death or resulted 
in a persistent or significant disability or 
incapacity.  
 An event that resulted in death.. 
AE = adverse event 
Any AE that changes in intensity or grade during a single occurrence of an AE will be recorded 
in the CRF at the highest level experienced by [CONTACT_423]. 
An AE that is assessed as severe should not be confused with an SAE.  Severity is a category 
used for rating the intensity of an AE (such as mild, moderate, or severe myocardial infarction).  
An AE, however, may be of relatively minor medical significance (e.g., a severe headache).  
Both AEs and SAEs can be assessed as severe.  An AE is considered serious when it meets 
criteria for one of the predefined outcomes described in Section [IP_ADDRESS] . 
[IP_ADDRESS]. Assessment of Causality 
The Investigator must estimate the relationship between study drug and the occurrence of each 
AE or SAE by [CONTACT_512832].  Elements to consider for this estimate 
include the history of the underlying disease, concomitant therapy, other risk factors, and the 
temporal relationship of the AE or SAE to exposure to study drug.  The Investigator must also  
Because of reporting timelines, the Investigator may have minimal information to include in the 
initial SAE report.  The Investigator, however, must always assess causality for every SAE 
before transmitting the SAE report.  The Investigator may change his or her opi[INVESTIGATOR_512813]310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 45 causality in light of follow-up information, with subsequent amendment of the SAE report.  
Causality assessment is 1 of the criteria used to determine regulatory reporting requirements, and 
should not be left blank on the CRF.  The same applies to AEs that are to be processed as SAEs.  
The causal relationship of the study drug to an AE will be rated according to the following 
3-point scale:  
 Unlikely:  Does not follow a reasonable temporal sequence from study drug 
administration; maenvironmental factors or other therapi[INVESTIGATOR_512814]:  Follows a reasonable temporal sequence from study drug administration; 
 environmental factors or 
other therapi[INVESTIGATOR_512815]: Clear temporal association with improvement on cessation of study drug. 
Reappears upon re-challenge or follows a known pattern of response to the study drug  
For regulatory purposes, the following definitions will apply:  
 Related Adverse Event:  
 
 Unrelated Adverse Event: An unrelated AE is an AE with a causality rating of 
 
[IP_ADDRESS]. Assessment of Expectedness 
An unexpected adverse drug experience is defined as any adverse drug experience, that is not 
listed in the current Investigator Brochure.  This includes events that may be symptomatically 
and pathophysiologically related to an event listed in the Investigator Brochure but differ from 
the event because of greater severity or specificity.  For example, under this definition, hepatic 
necrosis would be unexpected (by [CONTACT_14213]) if the Investigator Brochure only 
referred to elevated hepatic enzymes or hepatitis.  Similarly, cerebral thromboembolism and 
cerebral vasculitis would be unexpected (by [CONTACT_14214]) if the Investigator 
Brochure only listed cerebral vascular accidents.  The term unexpected, as used in this definition, 
refers to an adverse drug experience that has not been previously observed (i.e., included in the 
Investigator Brochure) rather than from the perspective of such experience not being anticipated 
from the pharmacological properties of the study drug. 
[IP_ADDRESS]. Procedures for Eliciting and Recording Adverse Events 
Investigator and study personnel will report all AEs and SAEs whether elicited during subject 
questioning, or discovered during physical examination, laboratory testing and/or other means 
and should be recorded on the CRF and/or SAE Report Form, as appropriate. 
[IP_ADDRESS].1.  Eliciting Adverse Events 
An open-ended or non-directed method of questioning should be used at each study visit to elicit 
the reporting of AEs.  
           
 
           
 
             
  
 
 
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 46 [IP_ADDRESS].2.  Recording Adverse Events 
The following information should be recorded on the Adverse Events CRF: 
 Description of the event using accepted medical terminology 
 Event onset and resolution dates 
 Whether the AE met serious criteria 
 Severity/grade 
 Relationship to study treatment or other causality 
 Outcome (final outcome) 
 Action taken with study drug 
[IP_ADDRESS].3.  Diagnosis vs. Signs or Symptoms 
In general, the use of a unifying diagnosis is preferred to the listing out of individual symptoms 
(e.g., Dyspnea is a symptom of Pneumonia, therefore, record the reached diagnosis of 
Pneumonia as the event term when determined).  Groupi[INVESTIGATOR_44971] a diagnosis should 
only be done if each component sign and/or symptom is a medically confirmed component of a 
diagnosis as evidenced by [CONTACT_512833].  If any aspect of a sign or symptom does 
not fit into a classic pattern of the diagnosis, report the individual symptom as a separate AE. 
[IP_ADDRESS]. Reporting Periods for Adverse Events and Serious Adverse Events 
The safety reporting period for all AEs and SAEs is from the time of informed consent to the 
follow-up visit at Week 12.  All SAEs that occur after the safety reporting period and are 
considered study treatment-related in the opi[INVESTIGATOR_512816]. 
Serious adverse events must be followed until significant changes return to baseline levels, the 
event stabilizes (recovering/resolving) or is no longer considered clinically significant by [CONTACT_3786], or the subject dies or withdraws consent.  All non-serious AEs will be followed 
through the follow-up visit at Week 12.  Certain non-serious AEs of interest should be followed 
until resolution, changes return to baseline levels, or study closure. 
[IP_ADDRESS]. Recording Serious Adverse Events 
For SAEs, record the event(s) on both the CRF and an SAE Report Form (paper or electronic).  It 
should be noted that SAEs that occur prior to initiation of study drug (e.g., due to a study 
protocol procedure) will be entered into the clinical database, but not entered into the safety 
database. 
The following should be considered when recording SAEs:  Death is an outcome of an event.  The event that resulted in the death should be 
recorded and reported on both an SAE Report Form and CRF. 
 For surgical or diagnostic procedures, the illness leading to the surgical or diagnostic 
procedure should be recorded as the SAE, not the procedure itself.  The procedure  
 
 
    
 
 
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 47 should be captured in the narrative as part of the action taken in response to the 
illness. 
[IP_ADDRESS]. Reporting of Serious Adverse Events 
Any SAE occurring after the subject signs the ICF must be reported to pharmacovigilance staff 
by [CONTACT_648], fax, or e-mail within 24 hours of the time the Investigator becomes aware of the SAE 
(Table 2).  Any SAE reported by [CONTACT_512834] (Table 2).  Urgent reporting of SAEs is required for the 
following reasons: 
1. To enable the Sponsor to fulfill the reporting requirements to the appropriate regulatory 
authority 
2. To facilitate discussion between the Sponsor and the Investigator about appropriate 
follow-up measures (if necessary) 
3. To facilitate the SInvestigators or sites in a multicenter study 
4. To facilitate reporting unanticipated problems involving risk to subjects to the IRB 
Table 2: Timeline for Reporting Serious Adverse Events 
Initial SAE Report Follow-up SAE Report 
Time Frame Document Time Frame Document 
24 hours SAE report 7 days Updated SAE report 
SAE = serious adverse event. 
The SAE report will be completed as thoroughly as possible, including the following: 
 Subject identification information 
 Event term 
 All available details about the SAE 
 Causality of each SAE  
 Signature [CONTACT_512844].  If 
additional information to complete the SAE report is needed, the Investigator will not wait 
before notifying pharmacovigilance staff of the SAE.  The SAE report will be updated by [CONTACT_512835]. 
[IP_ADDRESS]. Pregnancy 
All pregnancies or suspected pregnancies occurring in either a female subject or female partner 
of a male subject are immediately reportable events. 
In the event that a pregnancy or suspected pregnancy (including elevated beta-human chorionic 
gonadotropin or positive pregnancy test in a female subject) should occur while the subject is on 
study drug, or within 120          
 
 
 
 
 
              
PMN310-101 Version 2.0; [ADDRESS_663648] 
notify immediately about the outcome of the pregnancy (normal or abnormal outcome) by 
[CONTACT_512836]-up Report Form. 
If the outcome of the pregnancy was abnormal (e.g., spontaneous abortion), the Investigator 
should report the abnormal outcome as an AE.  If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to the study pharmacovigilance group within [ADDRESS_663649] to 
causality, as SAEs.  In addition, any infant death after 30 days that the Investigator suspects is 
related to the in-utero exposure to the study drug should also be reported to the study  
Male subjects:  If a female partner of a male subject receiving study drug becomes pregnant, the 
male subject taking study drug should notify the Investigator, and the pregnant female partner 
should be advised to call their healthcare provider immediately.       
            
PMN310-101 Version 2.0; [ADDRESS_663650] DISCONTINUATION 
8.1. Study Termination 
If the Sponsor, Investigator, Medical Monitor, or appropriate regulatory officials discover 
conditions arising during the study that indicate that the study should be halted or that the site 
should be terminated, this action may be taken after appropriate consultation among the Sponsor, 
Investigator, and Medical Monitor.  Conditions that may warrant termination of the study 
include, but are not limited to, the following: 
 The discovery of an unexpected, serious, or unacceptable risk to subjects enrolled in 
the study 
 A decision on the part of the Sponsor to suspend or discontinue testing, evaluation, or 
development of the product 
 A study conducted at a single site in a multicenter study also may warrant termination 
under the following conditions: 
 Failure of the Investigator to enroll subjects into the study at an acceptable rate 
 Failure of the Investigator to comply with pertinent regulations of appropriate 
regulatory authorities 
 Submission of knowingly false information from the site to the Sponsor, Medical 
Monitor, or appropriate regulatory authority 
 Insufficient adherence to protocol requirements 
Study termination and follow-up will comply with conditions set forth in ICH E6, Guideline for 
Good Clinical Practice, Sections 4.12, 4.13, 5.20, and 5.21. 
8.2. Removal or Early Withdrawal of Subjects from Therapy or 
Assessment 
8.2.1. Removal of Subjects from Therapy or Assessment 
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
care. 
The Sponsor or its designee must be notified if a subject is withdrawn from study treatment or 
and CRF.  
Subjects who withdraw from treatment prematurely should complete an Early Termination Visit 
(Section 6.3 ) as soon as possible. 
[IP_ADDRESS]. Potential Criteria for Withdrawal from Study 
Any of the following events are possible reasons for subject discontinuation from the study: 
 Subject is noncompliant with the study procedures or medications. 
 Subject takes prohibited concomitant medications as defined in this protocol.  
 
 
 
 
 
 
               
 
 
PMN310-101 Version 2.0; [ADDRESS_663651] be discontinued from the study if any of the following events occur: 
 Adverse events (AEs) that are intolerable (as determined by [CONTACT_423]) or that put 
the subject at additional risk as judged by [CONTACT_512837]. 
 Subject withdraws his or her consent. 
 Confirmation of subject pregnancy during the study, as evidenced by a positive 
pregnancy test. 
 
subject. 
 The Sponsor or a regulatory agency terminates the study. 
8.3. Replacement of Study Subjects 
Sentinel group subjects who discontinue before Day 7 will be replaced, unless they discontinued 
due to an SAE related to study drug. 
Non-sentinel group subjects who discontinue before Day 7 may be replaced at the discretion of 
the Sponsor and the SRC.  
 
 
 
 
            
 
PMN310-101 Version 2.0; [ADDRESS_663652] of 8 subjects (6 PMN310, 2 placebo).  The sample size of 8 subjects per 
cohort is based on feasibility and precedent for Phase 1 FIH studies.  The sample size of this 
study is not based on statistical considerations;  
 
 
9.3. Analyzed Population Sets 
 The safety population will include all subjects who receive study drug. 
 The PK population will include all subjects who receive study drug and have at least 
[ADDRESS_663653] 1 postdose 
LP. 
9.4. Statistical Analyses 
9.4.1. Safety Analysis 
Only subjects in the safety population will be included in the safety analysis.  Safety and 
tolerability results including vital signs, MRI if/when indicated, ECGs, laboratory test results, 
physical and neurological examinations, AEs/SAEs, serum ADA, and C-SSRS from this study 
will be assessed using summary statistics by [CONTACT_9084] (e.g., n, mean, median, minimum, maximum, 
for continuous endpoints; n and percentages for binary and categorical endpoints).  All placebo 
subjects from the different cohorts will be combined into a single group for summary purposes. 
9.4.2. Pharmacokinetic Analysis 
The PK population will be used for the PK analysis.  PMN310 serum concentration data will be 
listed by [CONTACT_9084], subject, and visit/sampling time point.  Descriptive summary statistics will be 
provided by [CONTACT_117316]/sampling time point.  Summary statistics will include mean 
(arithmetic and geometric), standard deviation (SD), coefficient of variation (CV) (arithmetic 
and geometric), median, minimum, and maximum.  Concentrations below lower limit of 
quantitation will be treated as zero in summary statistics. 
On the basis of PMN310 concentration -time data, the following PK parameters will be 
estimated using standard noncompartmental methods using Phoenix® WinNonlin® Version 8.0 or 
higher:  
 
 

PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 52  AUC0-t, calculated by [CONTACT_143624]-log trapezoidal rule: linear trapezoidal rule up 
to maximum concentration, and then a log trapezoidal rule for the remainder of the 
curve, where t corresponds to the last measurable time point 
 AUC0- = AUC 0-t + Ctz, where C t is the last measurable serum PMN310 
z is the terminal elimination rate constant calculated by [CONTACT_512838]-
linear regression of the terminal elimination phase of the serum concentration versus 
time curve 
 Cmax of PMN310 from the observed PMN310 concentration-time data 
 Tmax of PMN310 from the observed PMN310 concentration-time data 
 t1/2 z 
 Vd = volume of distribution during the terminal phase 
 CL = total body clearance 
 = terminal elimination rate constant  
PK parameters will be summarized by [CONTACT_38071] (e.g., n, arithmetic 
means, geometric means, SD, %CV, median, minimum, and maximum).  Figures will be created 
to display mean and individual subject PMN310 concentration time curves in serum on both a 
linear and logarithmic scale.   
Dose proportionality of PMN310 will be assessed using a power model.  The PK parameters to 
be analyzed are C max and AUC last.  A natural logarithmic transformation will be applied for the 
power model, which implies to a general linear model to the log transformed PK parameter with 
a fixed continuous log-).  An 
assessment of the relationship between the doses of PMN310 and the PK parameters will be 
obtained from the estimate of the slope and the corresponding 90% confidence interval. 
Cerebrospi[INVESTIGATOR_872] (CSF) PMN310 concentrations will be listed by [CONTACT_9084], participant and 
summarized by [CONTACT_9084].  Summary statistics will include mean (arithmetic and geometric), SD, 
CV (arithmetic and geometric), median, minimum and maximum.  
  
   
 
 
     
 
 
  
           
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 53 10. QUALITY CONTROL AND QUALITY ASSURANCE 
The following steps will be taken to ensure the accuracy, consistency, completeness, and 
reliability of the data: 
 Training of site personnel on all protocol procedures during site initiation visits 
 Routine study site monitoring 
 CRF review against source documents 
 Data management quality control checks 
In addition, the Sponsor or designee may conduct periodic site audits.   
10.1. Study Monitoring and Site Audits 
Representatives designated by [CONTACT_512839], ICH, national and local regulations and guidelines.  During the clinical study, 
Clinical Monitors will visit the study site(s) on a regular basis to assess and assure satisfactory 
enrollment rates, data recording, maintenance of required regulatory documentation, and 
protocol compliance.  The Investigator must ensure that all requested materials, including subject 
charts, CRFs, source documents, laboratory records, and study drug inventory records are 
available to the Clinical Monitor.  The Investigator must also ensure that he/she and other 
qualified personnel are available at each study site visit to discuss and resolve any study-related 
issues. 
As stipulated by 21 CFR 312.58 and ICH guidelines for Good Clinical Practice (GCP), 
representatives of the Sponsor, the FDA, or other regulatory agencies may conduct periodic 
study site audits.  These representatives must have access to all requested materials, including 
subject charts, CRFs, source documents, laboratory records, and study drug inventory records. 
10.2. Case Report Forms 
Authorized site personnel will complete electronic CRFs designed for this study and provided by 
[CONTACT_2024].  The Investigator will ensure that the CRFs are accurate, complete, legible, and 
completed in a timely fashion.  CRF completion guidelines and instructions for transmitting the 
CRFs to the Sponsor or designee will be provided.   
10.3. Source Documentation 
As stipulated by [ADDRESS_663654] be maintained to document the treatment and study course of subjects, and to 
substantiate the integrity of the clinical study data submitted for review to the regulatory 
agencies.  Source documentation for clinical studies includes, but is not limited to, the following:  Hospi[INVESTIGATOR_307], clinic, or office records documenting study visits, including treatments with 
PMN310 and other treatments or procedures 
 Medical history and physical examination information 
 Laboratory and special assessments results  
 
 
 
 
 
 
PMN310-101 Version 2.0; [ADDRESS_663655] ensure that source documentation is accessible to appropriate study 
personnel for purposes of study monitoring and site audits as described in Section 10.1 .   
10.4. Data Management 
Data will be collected on CRFs as described in Section 10.2 , entered into a clinical database, 
reviewed for data quality, completeness, timeliness of data entry, and protocol compliance, and 
analyzed by [CONTACT_512840].    
PMN310-101 Version 2.0; [ADDRESS_663656] or Independent Ethics Committee 
This protocol, the informed consent, Investigator Brochure, and any other relevant supporting 
information (e.g., all advertising materials) must be reviewed and approved by [CONTACT_413578]/Independent Ethics Committee (IEC) before study initiation.  A letter confirming IRB/IEC 
approval of the protocol and informed consent, and a statement that the IRB/IEC is organized 
and operates according to GCP guidelines and the applicable laws and regulations, must be 
provided to Sponsor before screening subjects for the study.  Amendments to the protocol must 
also be approved by [CONTACT_1201]/IEC and local regulatory agency, as appropriate, before the 
implementation of changes in this study (Section 11.3). 
The Investigator is responsible for informing the IRB/IEC of the progress of the clinical study as 
appropriate and updating the IRB/IEC at least annually.  Investigators are required to promptly 
submit Safety Reports or other updated safety information (e.g., amended Investigator Brochure) 
to the IRB/IEC. 
The IRB/IEC may have other specific reporting requirements with which the Investigator is 
expected to comply. 
11.2. Ethical Conduct of the Study 
The study will be conducted in accordance with the ethical principles that have their origins in 
the Declaration of Helsinki.   
11.3. Protocol Revisions and/or Deviations 
Substantive changes in the protocol include changes that affect the safety of subjects or changes 
that alter the scope of the investigation, the scientific quality of the study, the experimental 
design, dosages, assessment variable(s), the number of subjects treated, or the subject-selection 
criteria.  Such changes must be prepared as a protocol amendment by [CONTACT_512841].  A protocol 
amendment must receive IRB/IEC approval before implementation.  In parallel with the 
IRB/IEC approval process, the protocol amendment will be submitted to the appropriate 
regulatory authority as an amendment to the regulatory submission under which the study is 
being conducted.  If a protocol amendment requires changes in the ICF, the revised ICF prepared 
by [CONTACT_512842], Medical Monitor, and the IRB/IEC 
before implementation. 
Departures from the protocol are allowed only in situations that eliminate an immediate risk to a 
subject and that are deemed crucial for the safety and wellbeing of that subject.  The Investigator 
or the attending physician also will contact [CONTACT_512843] a departure.  These departures do not require preapproval by [CONTACT_1201]; however, the IRB 
and Medical Monitor must be notified in writing as soon as possible after the departure has been 
made.  In addition, the Investigator (for the protocol deviation and the ensuing events.           
PMN310-101 Version 2.0; [ADDRESS_663657] Information and Consent 
The IRB/IEC-approved ICF and Subject Information Sheet, if required, must be provided by [CONTACT_429].  The Investigator or designee must explain to the subject the purpose and nature of the 
study, the study procedures, the possible adverse effects, and all other elements of consent as 
defined in 21CFR Part [ADDRESS_663658] (HIPAA)-compliant authorization containing the mandated core elements and requirements 
prior to participating in a clinical study. 
11.5. Personal Data Protection 
third parties other than those noted below is prohibited.  This information is protected as 
mandated by [CONTACT_2373] (45 CFR Subpart E) for subjects in the [LOCATION_002].  Further, each subject 
is assigned a unique identification number to correspond to data entered into computer databases 
and used in reports.   
Because of the experimental nature of this treatment, the Investigator agrees to allow the 
IRB/IEC, representatives of the Sponsor, its designated agents and authorized employees of the 
appropriate regulatory agencies to inspect the facilities used in this study and, for purposes of 
verification, allow direct access to the hospi[INVESTIGATOR_512817].  This includes providing de-identified copi[INVESTIGATOR_512818].  A statement to this effect will be included in the informed consent and 
permission form authorizing the use of protected health information. 
physician or other appropriate medical            
    
              
      
       
      
PMN310-101 Version 2.0; 22 September 2023 
PMN310 ProMIS Neurosciences 
Confidential Page 57 12. STUDY ADMINISTRATION 
12.1. Investigator Site File 
The following documentation concerning the Investigator and study staff, the IRB/IEC, and the 
institution is required before site initiation: 
 Signed protocol and protocol amendment(s) if applicable 
 Signed statement of Investigator (if required by [CONTACT_61462]) 
 Institutional review board IRB/IEC composition 
 Document indicating IRB/IEC approval of the final protocol and amendment(s) if 
applicable (to include name, address, and chairperson of the IRB/IEC) 
 Document indicating IRB/IEC approval of the final and revised ICF if applicable (to 
include name, address, and chairperson of the IRB/IEC) 
 Blank copy of the IRB/IEC-approved final and revised ICF 
 Document indicating IRB/IEC approval of subject materials study advertisement, if 
applicable (to include name, address, and chairperson of the IRB/IEC) 
  
 Laboratory certification or accreditation and normal ranges for tests that are 
performed in the laboratory for study assessments 
 Curricula vitae and if applicable, medical license for the Investigator and 
subinvestigator(s) listed on the Form FDA 1572 of the study 
 Financial disclosure (as required) for the Investigator and subinvestigator(s) listed on 
the Form FDA 1572 of the study 
obligations, the Investigator Brochure, the clinical study protocol and amendments, safety 
information, clinical study material, biological samples, laboratory, Pharmacy Manual, 
monitoring activities, Sponsor/Investigator/Medical Monitor correspondence, will be kept on-site 
in study site specific binders. 
12.2. Retention of Study Records 
According to ICH E6, Section 4.9, all CRFs, as well as supporting paper and electronic source 
documentation and administrative records, must be retained by [CONTACT_31201] 
[ADDRESS_663659] in the [LOCATION_002].  
These documents should be retained for a longer period, however, if required by [CONTACT_494163].  The Sponsor is responsible for 
informing the Investigator and institution as to when these documents no longer need to be 
retained.  No study documents will be destroyed or moved to a new location without prior 
written approval from the Sponsor.  If the Investigator relocates, retires, or withdraws from the  
 
  
 
 
 
         
 
 
 
             
PMN310-101 Version 2.0; [ADDRESS_663660] be approved by [CONTACT_2728].      
PMN310-101 Version 2.0; [ADDRESS_663661] be obtained.  Additional details provided in Section 7.1.9 . 
11 Pharmacokinetic blood sampling for serum PMN310 concentrations should be performed as follows: 
 Day 1: before infusion, at the end of infusion, and at 0.5, 1, 2, 4, 8, and 12 hours after the end of infusion 
o Acceptable windows for PK sampling are as follows (exact time of PK collection is to be recorded):   
 Pre-dose sample to be collected within [ADDRESS_663662]-dose samples to be collected ± [ADDRESS_663663]-dose samples to be collected ± 10 minutes 
 Day 2 (24 and 36 hours) 
o Acceptable window for PK sampling is ± 30 minutes (exact time of PK collection is to be recorded) 
 Day 3 (48 hours) and Day 4 (72 hours) 
o Acceptable windows for PK sampling are ± 60 minutes (exact time of PK collection is to be recorded) 
 Days 8, 15, 29, 43, 57, 85 
12 Note: Residual or unused  serum and CSF samples will be stored for future use for the measurement of biomarkers.  For Day 120, only serum will be stored for 
the measurement of biomarkers since CSF will not be collected at Day 120.  Additional details are provided in Section 7.1.12 . 
13 CSF samples will be obtained via lumbar puncture (LP).  All dose cohorts will have LPs on Day 3 and Day 29.  The timing of additional LPs will be based on 
the available serum PK and CSF concentrations of PMN310 from prior cohorts, and may potentially include Day 15, Day 57, or Day 85 (shown in parentheses in the Schedule of Assessments).  The timing of LPs will be communicated to the Investigator who will inform the subject.  Coagulation (INR/PT/PTT and 
platelet) results within [ADDRESS_663664] about the 
timing of the optional visit.  Additional details are provided in Section 6.2.3 . 
  
 
 
  
 
             